Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed
Chicago, IL – August 15, 2025 – Today, Zacks Equity Research discusses Envista Holdings NVST, BioLife Solutions BLFS, InfuSystems Holdings INFU and MariMed MRMD.
Industry: Medical Products
Link: https://www.zacks.com/commentary/2711577/4-medical-product-stocks-to-watch-from-a-challenging-industry
The Zacks Medical - Products industry is likely to remain under pressure through the rest of 2025. While procedural volumes are stable, growth is slowing and high-cost, advanced procedures face adoption and funding hurdles. Capital spending is uneven, with longer sales cycles and reliance on expensive technologies creating risks. Innovation in electrophysiology, structural heart, and AI imaging is struggling to translate into consistent revenues amid regulatory delays, competition and payer scrutiny.
Emerging markets face policy headwinds, notably China's margin-eroding volume-based procurement. Tariffs, component shortages, COVID testing declines and product discontinuations are further squeezing margins. Without a clear demand rebound or easing cost pressures, the risks led to continued underperformance for the sector.
However, industry participants, such as Envista Holdings, BioLife Solutions, InfuSystems Holdings and MariMed, have adapted to changing consumer preferences, and most of them are witnessing a rise in their share price. These companies also carry a favorable Zacks Rank.
Industry Description
The industry includes companies that provide medical products and cutting-edge technologies for healthcare services. These companies are primarily focused on research and development and cater to vital therapeutic areas like cardiovascular, nephrology and urology devices.
The increase in procedure volumes is driving sales, particularly for surgical products and services. At the same time, cost-cutting measures are helping companies improve their bottom-line performance.
However, the industry's profitability picture is under significant strain. Tariff-related expenses are cutting into margins, forcing companies into complex and costly supply-chain restructuring. Persistent component shortages, though less widespread than in prior years, continue to create inefficiencies and constrain output in certain product lines. Additionally, the sharp drop in COVID-relate
Major Trends Shaping the Future of the Medical Products Industry
AI, Medical Mechatronics & Robotics: The increasing adoption of minimally invasive, robot-assisted surgeries, automated home care, IT-driven patient management, and value-based payment models underscores the rising influence of AI in the Medical Products sector. At the forefront is mechatronics — a fusion of electronics, machine learning, and mechanical engineering — driving innovation across the industry. Companies are making significant progress in AI, robotics, and medical mechatronics, with robotic surgical platforms enabling less invasive procedures and reducing patient trauma.
Meanwhile, 3D printing is reshaping the landscape, now used to produce stem cells, blood vessels, heart tissue, prosthetics and skin. These advances highlight the sector's transformative shift toward precision, personalization and improved clinical outcomes.
Rising Demand for IVD: The COVID-19 pandemic led to a rise in global demand for diagnostic testing kits to curb the spread of the virus. Testing became a pressing need, leading to a shift in the IVD product pipeline, with many rapid, point-of-care devices entering development. Diagnostic kit manufacturers not only received emergency use authorization from the FDA but also bolstered production to help address testing shortages. Industry players anticipate significant demand for rapid diagnostic testing in the future and are poised to capitalize on this opportunity.
Emerging Markets Hold Promise: Driven by growing medical awareness and rising economic prosperity, emerging economies are experiencing strong demand for medical products. Factors such as aging populations, more relaxed regulatory environments, affordable skilled labor, increasing household wealth, and government investment in healthcare infrastructure make these markets highly attractive to global medical device companies.
Zacks Industry Rank
The Zacks Medical Products industry falls within the broader Zacks Medicalsector.
It currently carries a Zacks Industry Rank #149, which places it in the bottom 39% of more than 250 Zacks industries.
The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all member stocks, indicates bright near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present a few medical product stocks that you may want to consider for your portfolio, let's take a look at the industry's recent stock-market performance and valuation picture.
Industry Performance
While the industry has outperformed its own sector, it has underperformed the Zacks S&P 500 composite in the past year.
Stocks in this industry have collectively risen 5.1% against the Zacks Medical sector's decline of 19.9%. The S&P 500 has increased 17.2% in the same time frame.
Industry's Current Valuation
On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 21.4X compared with the S&P 500's 22.9X and the sector's 18.5X.
Over the past five years, the industry has traded as high as 27.4X and as low as 17.9X, with the median being at 22X.
4 Promising Medical Product Stocks
Envista Holdings enters the second half of 2025 with momentum from a solid first-half performance, supported by diversified growth across equipment, consumables, and specialty products. Continued strength in orthodontics, particularly Brackets & Wires and Spark Clear Aligners, will be augmented by product launches like Spark Retainers, AI-enhanced DTX Studio Clinic and Implant Direct scanning solutions. Penetration into dental service organizations (DSOs) and double-digit growth in emerging markets remain key levers.
Operational improvements, including a 15% G&A reduction and manufacturing expansion in Suzhou, China, support margin resilience and local-for-local supply strategies. Pricing actions and cost controls are expected to offset tariff pressures, while acquisitions add incremental growth. Strong demand in infection prevention, diagnostics, and implants should continue, with the third quarter benefiting from Spark Deferral revenue. Stable dental market conditions, coupled with strategic investments in sales, marketing, and R&D, position Envista to deliver on its raised guidance for 2025.
For this Brea, CA-based company, the Zacks Consensus Estimate for 2025 revenues is pinned at $2.61 billion. The consensus estimate for earnings is pegged at $1.12 per share. NVST delivered a trailing four-quarter average negative earnings surprise of 16.50%. Presently, the company sports a Zacks Rank #1 (Strong Buy).
BioLife Solution is set to benefit from strong demand recovery in cell and gene therapy (CGT) tools, as customer manufacturing activity continues to normalize. The recent integration of Astero, Sexton, and other acquired technologies expands its bioproduction solutions portfolio, allowing deeper penetration into high-growth biopharma segments. Expansion of the cryo-storage services footprint, particularly through the SciSafe network, positions the company to capture more recurring revenues.
Efforts to optimize manufacturing capacity and reduce COGS should support margin expansion. New product launches in media and biopreservation, alongside an expanded international sales presence, will help address broader customer needs. Strategic partnerships with therapy developers are expected to drive higher adoption of integrated workflow solutions. While macro uncertainty and biotech funding volatility remain potential headwinds, BioLife's diversified portfolio, operational efficiencies and exposure to commercial-stage CGT programs provide a solid foundation for growth through year-end.
For this Bothell, WA-based company, the Zacks Consensus Estimate for 2025 revenues indicates a year-over-year decline of 11.7%. The consensus estimate for earnings indicates growth of 171.4%. It delivered a trailing four-quarter earnings surprise of 123.61%, on average. Presently, the company sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here.
InfuSystem Holdings' growth trajectory in the second half of 2025 is anchored in its Device Solutions and Patient Services segments. Expansion of oncology and wound care programs, coupled with growing demand for infusion pumps and related disposables, is expected to lift volumes. The company is capitalizing on the broader adoption of negative pressure wound therapy (NPWT) through partnerships with large healthcare providers.
A stronger equipment rental base and fleet optimization efforts should further enhance recurring revenue streams. INFU is also investing in service coverage expansion and technology upgrades to improve customer experience and retention. Operational efficiencies from centralized distribution and maintenance hubs are set to reduce turnaround times and lower costs. The integration of new payer contracts and an expanding referral network will support top-line growth. Risks include reimbursement changes and hospital capital spending constraints, but INFU's recurring revenue model and expanding therapeutic reach are positioned to offset these pressures in the near term. Currently, INFU sports a Zacks Rank of 1.
For this Rochester Hills, MI-based company, the Zacks Consensus Estimate for 2025 revenues is pegged at $144.2 million. The consensus mark for loss is pinned at 26 cents per share. The company delivered a trailing four-quarter average earnings surprise of 79.17%.
MariMed's growth in the remainder of 2025 will be driven by retail expansion, wholesale penetration and new product innovation in the cannabis sector. The opening of new dispensaries in high-traffic markets, along with remodeling existing locations to improve customer flow, is expected to boost sales. The company is scaling cultivation capacity and optimizing yields to meet growing demand while lowering production costs. Expansion of branded product lines, including edibles and wellness offerings, should strengthen shelf presence and margins. Wholesale growth is supported by increasing distribution agreements across multiple states.
Investments in automation and processing technology aim to improve consistency and efficiency. Regulatory developments in key states, particularly around adult-use legalization, could provide an upside catalyst. While the industry faces pricing pressure and regulatory uncertainty, MariMed's vertically integrated model, brand strength, and disciplined capital allocation are set to underpin growth in the second half of the year. Currently, MRMD sports a Zacks Rank #1.
For this Springfield, MA-based company, the Zacks Consensus Estimate for 2025 loss is pinned at 3 cents per share. The company delivered a trailing four-quarter average earnings surprise of 50.00%.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report
InfuSystems Holdings, Inc. (INFU) : Free Stock Analysis Report
Envista Holdings Corporation (NVST) : Free Stock Analysis Report
MariMed Inc. (MRMD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
The rich already know how private equity mints money — and it's not from a 401(k)
The ultrawealthy are envied for many reasons. For instance, we wish we could access the same private-market investments that they favor. Now, after the White House issued an executive order on Aug. 7, you may be able to invest like the billionaires do. Homeowners rush to refinance as mortgage-rate plunge opens window of opportunity My wife and I are in our 50s and have $11 million. We're not leaving it to our kids. Is that wrong? You could receive up to $7,500 from the AT&T settlement. Here's how class-action suits work. But would you want to? The executive order allows ordinary retirement savers to invest in private assets and cryptocurrency. This will expand investment options for anyone with a 401(k) or similar tax-advantaged retirement plan. It is a big deal — opening part of America's $12.4 trillion defined-contribution market to private-asset managers. The largest private-equity firms and other asset managers are salivating at the opportunity to pitch this untapped market of retirement savers. Private assets encompass a range of investments that do not trade on a public exchange. Examples include hedge funds, private equity, private credit and infrastructure. The case for private assets is they can provide a buffer against inflation — plus steady returns. The downsides include high fees, illiquidity and complexity. The nation's biggest asset managers welcome the executive order. They want to develop funds that make private assets easier for people to buy, and argue that the added diversification serves savers' best interests. Larry Fink, chief executive of BlackRock BLK, says retirement savers should replace the traditional 60% stocks/40% bonds asset-allocation model with a 50/30/20 split: 50% stocks, 30% bonds and 20% private assets. Read: Larry Fink proposes an alternative to the 60/40 portfolio. It means more fees. Should you be excited about this widening menu of investment choices? It depends on whom you ask. Some investment professionals like the idea of making private assets more available to more people. 'Historically, a number of private-market strategies have produced higher performance and additional diversification in defined-benefit pensions,' says Peter von Lehe, head of investment solutions and strategy at Neuberger Berman. 'It's appropriate that a broader range of investors have access to private assets in their defined-contribution plans because of the potential for return and diversification that these long-term investments can provide.' However, von Lehe cautions that these investments are illiquid and 'have a higher degree of complexity.' He says his 'most appropriate use case' for private-market investments is through professionally managed target-date funds or other funds that allocate a percentage of defined-contribution money to these complex but potentially more lucrative alternatives. Read: Here's something the rich know about managing investment risk that can help you, too Financial advisers have differing views on the role of private assets in client portfolios. Steven Roge, a certified financial planner in Bohemia, N.Y., says private markets are not for everyone. 'It's for people in the wealth-accumulation phase, say 40 to 50 years old, who have a long time horizon and a high risk tolerance,' Roge says. 'And they have to be sophisticated enough to understand it. We know if they don't understand it, they may not stick with it.' Of the firm's 300 clients, he says that 'only about a dozen' fit the bill for adding private-market assets to their retirement accounts. Even with the expanded investment options that may result from the White House's action, Roge remains a fan of passive strategies for most investors. 'Indexing is how they will win over the long run,' he says. 'But some clients want something that's special and different' as they seek market-beating returns. Given the illiquidity of private assets, Roge anticipates setting expectations for those clients who tend to monitor their portfolio daily — and who engage in frequent trading. 'These private investments may only price four times a year,' Roge says. 'That's not enough action for certain clients who track their portfolio like a hawk.' In his personal portfolio, Roge uses private markets — especially private equity — to diversify his holdings. He says he allocates about 25% to alternative assets. 'It helps me sleep at night knowing my portfolio isn't being pushed around by the volatility of public markets,' he says. Roge adds that he is not concerned about the current high valuations of private-equity funds. 'The valuations [of private-equity funds] are more realistic than the erratic valuations we see in public markets on a daily basis,' he says. Other advisers are more skeptical of the White House executive order. 'It's less being done out of interest for the general public and more for private industry lobbying the [Trump] administration,' says Alex Ruda, an adviser in Silver Spring, Md. The executive order undoubtedly pleases asset managers and private-equity firms. For years, they've wanted to attract retirement savers' money. These savers bear primary responsibility for managing their 401(k) compared with today's older retirees, many of whom receive employer-funded defined-benefit pensions. While some younger savers enjoy picking their investments, others dread it. 'The average American worker isn't equipped to navigate these complex [private-market] investments,' Ruda says. 'And they may fall prey to a little performance chasing given where we are in the market cycle' — as private markets have outperformed publicly traded stocks since 2000. Ruda feels so strongly about not incorporating private assets into client portfolios that he's willing to forgo newcomers who express such interest. 'If I wanted to broaden my client base, I'd have to play to what they want,' he says. 'But I don't have to do that. So I'd say to them, 'I'm not the best fit.'' Read next: Here's what it's like to invest in private equity — and why you don't want it in your 401(k) More: As private equity enters retirement plans, is it too dangerous for average investors to jump in? I'm a senior who barely survives on $1,300 a month. No way could I live on $1,000. 'I am a senior citizen': My car needs $3,500 for repairs, but only has a trade-in value of $6,000. Do I bother fixing it?
Yahoo
18 minutes ago
- Yahoo
I'm a 67-year-old runner — these are the 6 best men's running shoes in 2025
Best running shoes for seniors from ASICS, Nike, Saucony and more. After years of playing soccer, squash and distance running on hard surfaces, I needed both my knees scoped (surgery to repair torn cartilage). Initially, my doctor recommended I stop running altogether. But after extensive badgering, he eventually gave me the green light to give running another shot, providing I took careful steps — literally. Steps as in: ramping up slowly (not unlike when I first began running as a late starter at 39), not running too hard or for too long, and importantly: choosing the right shoes. All of which has made it possible for me to keep running today as a 67-year-old. And why not? As studies conclusively show, running helps keep seniors young. Whether you're in your 30s, your 50s, your 60s or beyond, these shoes will help you to put your best foot forward. Best shoes for new runners One of the key differences between walking and running is that with running, you're hitting the ground with twice as much force. Experts estimate the force of walking is 1.5 times your body weight, while running can be 2-3 times. Thus, choosing shoes that provide enough support is a key consideration. Other good reads: Best running shoes for men in 2025, according to a competitive distance runner Best hiking shoes, clothes and accessories for men in 2025, according to an avid hiker Best men's running shoes for racing and marathons in 2025, according to a competitive athlete Best for runners returning from injury After almost 30 years of running, I've experienced pretty much every kind of injury you can think of. So I know first-hand how important it is when you start back up to find a balance between choosing shoes that provide adequate support, but are light and responsive enough to be a "go-to shoe" when you are ready to pick up the pace. Best trail shoes for running and hiking Running or walking on trails, especially hilly ones, is a great way to ramp up your cardio without stressing your body as much as running faster does. They can often provide a softer surface to run on, too. That said, I've been on many trails where you have to navigate stones, rocks and tree roots, so having shoes with good grip and protection should be top of mind.
Yahoo
18 minutes ago
- Yahoo
GM wows with Corvette, Cadillac concepts at Monterey Car Week
CARMEL, Calif – GM brought some Detroit muscle to the rarified air of Monterey Car Week — with a twist. While the Corvette nameplate falls under the Chevrolet brand, more and more it stands out on its own. At The Quail event in Carmel Valley, where multi-million dollar Paganis are displayed alongside priceless gullwing Mercedes SL coupes (and the parking lot is a show in and of itself), Corvette showed off two concepts that showed where the sportscar is headed in the future. The CX and its racing-inspired twin the CX-R, evoke supercar looks that go beyond the current 'C8' Corvette. The two concepts feature fighter jet-style interiors, with a trick canopy opening to boot. The twist — the CX is all electric, which is becoming a rarity at the higher end, and the CX-R features hybrid power. The racy CX-R will also be a drivable car in the Gran Turismo 7 racing game on PlayStation. And the response, beyond the oohs and ahhs, was strong for vehicles that aren't going on sale. 'We've had a number of customers that have already said, 'Could we buy one of those vehicles today?,'' said Rory Harvey, EVP and President of Global Markets, from the Quail Event to Yahoo Finance. Harvey, who essentially leads on all GM brands globally, noted that customers were asking to buy a vehicle with no pricing info, and wouldn't even be released. It was a good opportunity though, to collect future client info from buyers who typically own multiple cars. 'Just listening to the customers, the enthusiasts that are on the stage, I mean, the feedback is outstanding,' Harvey said. The UK-born exec noted that Corvette, in his opinion, was already at supercar levels, with competitive lap times at places like the Nurburgring in Germany, and 38% market share in the luxury sports car segment, making it the leader. Harvey's purview extends to Cadillac, where the luxury brand showed off its 'Elevated Velocity' concept, a cross-over style EV SUV meant to evoke the high-desert landscape. The new design language may hint at more curves and swooping design, as opposed to Cadillac's traditional angular features and vertical light bars. Regardless, Cadillac as a brand has been on a winning streak with its combination of traditional gas powered cars like the Escalade and CT5 sedans, and EVs like the Lyriq and Optiq. 'Cadillac now has done 12 consecutive quarters of year-on-year growth, which is absolutely superb. But in quarter two, Cadillac is now the number one luxury brand for EVs. So again, that's really, really strong,' Harvey said. 'We've launched so many new products over the course of the last two years, and that momentum continues to build. So we're looking at, how do we keep our foot on the accelerator pedal and build even further?' Harvey said he wasn't terribly concerned over the upcoming loss of the EV tax credit, because the brand would be able 'flex' into its other gas-powered offerings like the XT crossovers if its EVs were not price competitive. While a nice game plan, it doesn't address the fact the company invested heavily in EVs, and might take a hit to sales. Another challenge is tariffs, where GM took a big hit in the second quarter and stands to feel more pain in the second half of the year. Harvey noted the trade deals in place are mostly preliminary, so when the details come out the company will have a hard look at its manufacturing footprint, product portfolio in terms of territory, and where the company can minimize its tariff exposure. 'We've publicly stated that we believe that we can mitigate approximately 30% of the impact of tariffs; so, we're in a strong position at the moment,' Harvey said of GM's ability to pivot around President Trump's tariff war. Harvey still believes GM is in a great spot regardless of tariffs, and it's because of products like the current Corvette and Cadillac portfolio — cars that are selling well in the marketplace. 'If you looked at just General Motors sales in the US, we are the fastest growing brand, full stop. And if you look to the nearest competitor, they're about half the level of growth that we've got. So customers love our products.' Pras Subramanian is the lead auto reporter for Yahoo Finance. You can follow him on X and on Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
